#1 Clinical Trials Search in Europe

Bomedemstat

Bomedemstat, also known as MK-3543 or IMG-7289, is an innovative drug currently being studied in clinical trials for the treatment of various myeloproliferative neoplasms (MPNs). These trials are investigating its safety, efficacy, and potential benefits for patients with conditions such as polycythemia vera, essential thrombocythemia, and myelofibrosis. This article provides an overview of the ongoing research and potential implications of Bomedemstat in the field of hematology.

Table of Contents

What is Bomedemstat?

Bomedemstat is a new drug being developed to treat various blood disorders and certain types of cancer. It’s also known by several other names, including MK-3543, IMG-7289, and LSD1 inhibitor IMG-7289[1][2]. This medication is currently being studied in clinical trials to determine its safety and effectiveness in treating different conditions.

How Does Bomedemstat Work?

Bomedemstat works by inhibiting (blocking) an enzyme called lysine-specific demethylase 1 (LSD1)[3]. This enzyme plays a role in regulating blood cell production and the growth of certain cancer cells. By inhibiting LSD1, Bomedemstat may help to control the overproduction of blood cells in some blood disorders and potentially slow down or stop the growth of certain types of cancer cells.

What Conditions Does Bomedemstat Treat?

Bomedemstat is being studied for the treatment of several blood disorders and cancers, including:

  • Polycythemia Vera (PV): A condition where the body produces too many red blood cells[3].
  • Essential Thrombocythemia (ET): A disorder characterized by the overproduction of platelets in the blood[4].
  • Myelofibrosis (MF): A rare type of blood cancer that affects bone marrow function[1].
  • Acute Myeloid Leukemia (AML): A type of blood and bone marrow cancer[5].
  • Small Cell Lung Cancer (SCLC): A fast-growing type of lung cancer[2].

These conditions are all serious diseases that affect the blood or involve the rapid growth of cancer cells. Bomedemstat aims to help manage these conditions by regulating cell production or growth.

Clinical Trials and Research

Bomedemstat is currently being studied in various clinical trials to evaluate its safety and effectiveness. These trials are testing the drug in different scenarios:

  • As a standalone treatment for blood disorders like PV and ET[3][4].
  • In combination with other drugs, such as ruxolitinib for myelofibrosis[6].
  • Compared to standard treatments like hydroxyurea for ET[7].
  • In combination with venetoclax for relapsed or refractory AML[5].
  • Combined with immunotherapy (atezolizumab) for small cell lung cancer[2].

These trials are helping researchers understand how well Bomedemstat works, what doses are most effective, and what side effects may occur.

How is Bomedemstat Administered?

Bomedemstat is taken orally, usually in the form of capsules or tablets[3][8]. The dosage and frequency of administration can vary depending on the condition being treated and the specific clinical trial. In most studies, it is taken once daily, but the exact dose may be adjusted based on how a patient responds to the treatment.

Potential Side Effects

As with any medication, Bomedemstat may cause side effects. The full range of potential side effects is still being studied in clinical trials. Some of the effects being monitored include:

  • Changes in blood cell counts (red blood cells, white blood cells, and platelets)[3].
  • Bleeding events[3].
  • Thrombotic events (blood clots)[3].
  • Changes in spleen size[1].
  • Other general side effects that may be detected through regular blood tests and physical examinations.

It’s important to note that the safety profile of Bomedemstat is still being established through ongoing clinical trials.

Future Research and Combinations

Researchers are exploring various ways to use Bomedemstat, including:

  • Long-term safety and efficacy studies for blood disorders[9].
  • Combination therapies with other cancer treatments[6][5].
  • Potential use in other types of cancers or blood disorders not currently being studied.

As research continues, more information about Bomedemstat’s effectiveness, safety, and potential uses will become available. This ongoing work aims to provide new treatment options for patients with challenging blood disorders and cancers.

Aspect Details
Drug Name Bomedemstat (MK-3543, IMG-7289)
Mechanism of Action Lysine-specific demethylase 1 (LSD1) inhibitor
Administration Oral (capsules or tablets), once daily
Conditions Studied Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis
Primary Outcomes Safety, efficacy, pharmacokinetics, pharmacodynamics
Secondary Outcomes Spleen volume reduction, symptom improvement, blood count normalization
Trial Phases Phase 1, Phase 2, Phase 3
Key Measurements Adverse events, blood counts, spleen size, quality of life

FAQ

  • What is Bomedemstat? Bomedemstat is an orally administered drug that inhibits lysine-specific demethylase 1 (LSD1). It is being studied as a potential treatment for various myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis.
  • What conditions is Bomedemstat being tested for? Bomedemstat is being tested in clinical trials for several myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.
  • How is Bomedemstat administered? Bomedemstat is administered orally, typically once daily in the form of capsules or tablets. The dosage and duration of treatment may vary depending on the specific clinical trial and condition being studied.
  • What are the main goals of the Bomedemstat clinical trials? The main goals of the Bomedemstat clinical trials are to evaluate its safety, efficacy, pharmacokinetics, and pharmacodynamics in patients with myeloproliferative neoplasms. Researchers are also investigating its ability to reduce spleen size, improve blood cell counts, and alleviate symptoms associated with these disorders.
  • Are there any known side effects of Bomedemstat? As with any investigational drug, the full range of potential side effects is still being studied. Clinical trials are closely monitoring for adverse events, which may include changes in blood cell counts, gastrointestinal symptoms, and other effects. The safety profile of Bomedemstat is a key focus of ongoing research.

Ongoing Clinical Trials on Bomedemstat

  • Study Comparing Bomedemstat and Hydroxycarbamide for Patients with Essential Thrombocythemia

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Denmark France Germany Hungary Italy +3

  • Study on Bomedemstat for Patients with Essential Thrombocythemia Not Responding to or Intolerant of Hydroxyurea, Comparing with a Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France Germany Hungary Italy The Netherlands +4

  • Study on the Safety of Bomedemstat for Patients with Myeloproliferative Neoplasms Who Participated in a Previous Bomedemstat Study

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Myeloproliferative Neoplasms (MPNs): A group of blood cancers characterized by the overproduction of certain types of blood cells in the bone marrow.
  • Polycythemia Vera (PV): A type of MPN characterized by an overproduction of red blood cells, which can lead to increased blood thickness and risk of blood clots.
  • Essential Thrombocythemia (ET): A type of MPN characterized by an overproduction of platelets, which can increase the risk of blood clots or bleeding.
  • Myelofibrosis (MF): A type of MPN characterized by scarring of the bone marrow, which can lead to decreased production of blood cells and enlargement of the spleen.
  • Lysine-specific demethylase 1 (LSD1): An enzyme involved in gene regulation that Bomedemstat targets to potentially treat myeloproliferative neoplasms.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and therapeutic effects.
  • Splenomegaly: Enlargement of the spleen, which is a common symptom in some myeloproliferative neoplasms.
  • Hematocrit: The percentage of red blood cells in the blood, which is often elevated in polycythemia vera.
  • Thrombotic events: Formation of blood clots that can obstruct blood flow, which is a risk in some myeloproliferative neoplasms.
  • Cytoreductive therapy: Treatment that reduces the number of blood cells, often used in managing myeloproliferative neoplasms.
  • Durable Clinicohematologic Response (DCHR): A sustained improvement in blood cell counts and clinical symptoms in response to treatment.

References

  1. https://clinicaltrials.gov/study/NCT03136185
  2. https://clinicaltrials.gov/study/NCT05191797
  3. https://clinicaltrials.gov/study/NCT05558696
  4. https://clinicaltrials.gov/study/NCT04254978
  5. https://clinicaltrials.gov/study/NCT05597306
  6. https://clinicaltrials.gov/study/NCT05569538
  7. https://clinicaltrials.gov/study/NCT06456346
  8. https://clinicaltrials.gov/study/NCT06596668
  9. https://clinicaltrials.eu/trial/study-on-the-safety-of-bomedemstat-for-patients-with-myeloproliferative-neoplasms-who-participated-in-a-previous-bomedemstat-study/